1/ Bio Ecosystem Science Updates From clinical studies to real-world pilots, Bio's pipeline of research projects is rapidly advancing. Track scientific progress across decentralized biotechs in the Bio Network 🧵↓

2/ @vita_dao Portfolio now includes 16 longevity programs, including: • VitaSTEM: Stem cell rejuvenation research co-designed by Aubrai • Cyclarity Therapeutics: Phase 1 clinical trial in progress. • BE Therapeutics: Advancing brain-tissue graft models. • Gero: Partnered

x.com/i/article/1979…

If I ever die I’m going to be so mad at the longevity research community

Ladies if you go to his apartment and his fridge is full of sequencing primers for his plasmid collection you DO NOT date him you deserve a man who does whole plasmid sequencing

Pavel Durov(Telegram CEO) reveals the shocking truth about alcohol and why he avoids it:

Final week to apply! Become a host lab and help train the next generation of scientists working to understand and address the root causes of aging. Learn more and apply: ow.ly/HyF750XiVyg

I got rejected by 144 investors before raising $150M for my $200M+ rev/year startup. After 144 rejections, I started questioning our approach. Were we solving the right problem? What were we doing wrong? Why weren’t investors seeing what we were seeing? Were we the right

Scientists around the world are saying the same thing: “Institutions are crumbling. Costs are skyrocketing. There has to be a better way to move research forward.” And they’re right. We can do better. DeSci is how we rebuild the bridge between discovery and delivery.

VitaDAO Community Call - This Friday @ 5pm CET! 🔬 What's on deck: - VitaLabs Season 1 - Project reports & outcomes from our first cohort - VitaLabs Season 2 - Big announcement & roadmap reveal! - Aubrai IPT - Latest on launches & Roadmap - Portfolio Companies - What our

We’re live in 10 minutes 🧬 Tune in to get an early look at Season 2 and what’s coming next! 🔔 Set a reminder: x.com/i/spaces/1rmxP…

Reprogramming shows promise, but safety remains a critical challenge. I hypothesized that calming the niche first could make partial reprogramming both effective and safe. Across thousands of studies, a consistent pattern emerged: Aging cells are trapped in a rigid, inflamed

Today, BillionToOne went public, becoming YC's 4th biotech IPO. As a company that quietly provides societally important infrastructure, BillionToOne is less well known than they deserve to be. Here is their story, from grad students to IPO. BillionToOne is the rare company

We are live

Today, we're announcing Episteme, a new type of R&D company that recruits exceptional scientists to pursue high-impact ideas. Science isn’t bottlenecked by the availability of talent, but by places where they can do their best work. Scientific progress has driven human

new updates coming soon for Aubrai 👀